News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2019

New Micro-Simulation Study in Cancer Medicine Finds Epi proColon® Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer

PDF – Adherence rates and screening intervals recognized as decisive elements of successful screening strategies Berlin (Germany), 29 November, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), today reported on micro-simulation model results indicating that Epi proColon®, a colorectal cancer (CRC) screening test approved for patients who are unwilling or unable to be […]

Read more

Epigenomics AG Reports Financial Results for the First Nine Months 2019

PDF Berlin (Germany) and San Diego, CA (USA), November 19, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the “Company”) today announced its financial results (IFRS, unaudited) for the first nine months of 2019. Major Events After the End of the Reporting Period On November 7, 2019, after the end of the reporting period, Epigenomics […]

Read more

Epigenomics AG Announces Conference Call with Authors Presenting at the European Public Health Conference

PDF Berlin (Germany) and San Diego, CA (U.S.A.), November 15, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced that Dr. Medhi Najafzadeh, PhD and Dr. Elvira D’Andrea, MD, MPH, two of the lead authors of the microsimulation model comparing outcomes of colorectal cancer screening methods, including the Epi proColon® blood test, will participate […]

Read more

Epigenomics AG successfully completes capital increase

NOT FOR PUBLICATION, DISTRIBUTION OR TRANSMISSION TO OR WITHIN THE UNITED STATES OF AMERICA, CANADA, JAPAN AND AUSTRALIA. PDF Berlin, 7 November 2019 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) has placed the new shares from the capital increase resolved on October 17, 2019 in an amount of EUR 7,506,152.00. Accordingly, the Company’s […]

Read more

Epigenomics AG: No operational reasons for sharp decline in share price

PDF Berlin (Germany) and San Diego, CA (U.S.A.), 4 November, 2019 – The Epigenomics share price today recorded a decline of around 16% with high trading volumes, closing at a price of EUR 0.93 on the XETRA exchange. The management of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “company”) makes it clear that […]

Read more

Epigenomics AG sets subscription price at EUR 1.11 per new share

PDF NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN AND AUSTRALIA. Epigenomics AG sets subscription price at EUR 1.11 per new share Berlin, 31 October 2019 – The Executive Board of Epigenomics AG (FSE: ECX; OTCQX: EPGNY; the “Company”) resolved today, with approval of […]

Read more